N-[5-[4-[(6-cyano-3-pyridinyl)Methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-cyclopropanecarboxaMide - Names and Identifiers
Name | N-[5-[4-[(6-Cyano-3-pyridinyl)methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl] cyclopropanecarboxa
|
Synonyms | CS-1887 GLPG0634 GLPG634 analog GLPG0634 analog GLPG0634 analog, Filgotinib analog N-[5-[4-[(6-Cyano-3-pyridinyl)methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl] cyclopropanecarboxa N-[5-[4-[(6-cyano-3-pyridinyl)Methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-cyclopropanecarboxaMide N-(5-(4-((6-cyanopyridin-3-yl)methoxy)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide N-[5-[4-[(6-Cyano-3-pyridinyl)Methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl] cyclopropanecarboxaMide (GLPG0634) N-[5-[4-[(6-Cyano-3-pyridinyl)methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-cyclopropanecarboxamide GLPG0634 analogue GLPG0634 N-[5-[4-[(6-Cyano-3-pyridinyl)methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-cyclopropanecarboxamide
|
CAS | 1206101-20-3
|
N-[5-[4-[(6-cyano-3-pyridinyl)Methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-cyclopropanecarboxaMide - Physico-chemical Properties
Molecular Formula | C23H18N6O2
|
Molar Mass | 410.43 |
Storage Condition | -20°C |
In vitro study | In cell lines, GLPG0634 inhibited JAK1/JAK3/γc signaling induced by IL-2 and IL-4 and JAK1/TYK2 type II receptor signaling induced by IFN-αB2 with an IC50 in the range of 150 to 760 nM. At the cellular level, GLPG0634 is more selective for JAK/STAT signaling comprising JAK1 than JAK2 kinase. In addition, GLPG0634 also inhibits the proliferation of Th1,Th2, and Th17 cells. |
In vivo study | After oral administration, the absolute bioavailability was moderate in rats (45%) and higher in mice (100%). GLPG0634 (30 mg/kg per day (RAT);50 mg/kg twice a day (mouse)) dose-dependently reduces inflammation, cartilage, and bone degradation. |
N-[5-[4-[(6-cyano-3-pyridinyl)Methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-cyclopropanecarboxaMide - Preparation solution concentration reference
| 1mg | 5mg | 10mg |
---|
1 mM | 2.436 ml | 12.182 ml | 24.365 ml |
5 mM | 0.487 ml | 2.436 ml | 4.873 ml |
10 mM | 0.244 ml | 1.218 ml | 2.436 ml |
5 mM | 0.049 ml | 0.244 ml | 0.487 ml |
Last Update:2024-01-02 23:10:35
N-[5-[4-[(6-cyano-3-pyridinyl)Methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-cyclopropanecarboxaMide - Introduction
GLPG0634 is a selective small molecule Janus kinase (JAK) inhibitor that regulates immune and inflammatory processes by inhibiting JAK1 and JAK2 activity. It is studied for the treatment of a series of autoimmune diseases, such as rheumatoid arthritis, bone hyperplasia and so on.
About the preparation method, N-[5-[4-[(6-Cyano-3-pyridinyl)methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl] cyclopropanecarboxa is prepared in the laboratory by synthetic organic chemistry methods. Specific synthetic routes and methods may require reference to relevant research literature or patents.
Last Update:2024-04-09 21:49:45